Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics.

Johannes A KroesKim de Jong Simone HashimotoSander W ZielhuisEric N van RoonJacob K SontAnneke Ten Brinke

Published in: ERJ open research (2023)

In addition to baseline characteristics, treatment outcomes at 3 months contribute to the prediction of benralizumab response at 1 year in patients with severe eosinophilic asthma. Prediction tools as proposed in this study may help physicians optimise the use of costly biologics.

Keyphrases

primary care
chronic obstructive pulmonary disease
lung function
early onset
air pollution